The treatment strategy for mesenchymal tumors of the gastrointestinal tract is based upon typing of the tumor. Especially differential diagnosis of gastrointestinal stromal tumors (GISTs) to leiomyomas is crucial for determining radicality of surgery. L1 cell adhesion molecule (CD171) plays an essential role in tumor progression. The aim of this study was to determine expression of L1 in GISTs, smooth muscle tumors, desmoid-type fibromatosis and peripheral nerve sheath tumors (PNSTs). We retrospectively analyzed a total of 129 surgically resected primary tumors or metastases of 72 GISTs, 29 smooth muscle tumors, seven PNSTs and 21 desmoid-type fibromatosis by immunohistochemistry for c-kit, CD34, smooth muscle actin, desmin, vimentin, S-100 and L1 expression. L1 expression was detected in 53 (74%) of 72 GISTs but in none of 29 smooth muscle tumors or 21 desmoid-type fibromatosis (Po0.01 by Fisher's test). In all, four (57%) of seven peripheral nerve sheath tumors were L1-positive. Survival analysis of 55 surgically completely resected GISTs presenting without metastasis at initial diagnosis revealed no tumor-specific death among L1-negative patients (P ¼ 0.13 by log-rank test; median follow-up time 41 months) and one recurrence was observed (P ¼ 0.12). Interestingly high levels of L1 were seen in tumor vascular endothelial cells of smooth muscle tumors and PNSTs, but not in GISTs. Our data show that L1 is highly expressed in GISTs but not in smooth muscle tumors and desmoid-type fibromatosis being important differential diagnoses. The trend towards a reduced survival of L1-positive patients in this study has to be further evaluated in future trials with higher patient numbers.
Gastrointestinal stromal tumors (GISTs) are a heterogeneous group of tumors originating from the interstitial cells of Cajal that are located in the nerve plexus of the muscularis in the gut wall. 1 On primary manifestation the outcome of GISTs is hardly predictable and patients have a bad prognosis once relapse or metastasis is discovered. 2, 3 The remarkable antitumor activity of the protein kinase inhibitor Imatinib (Glivec s ) in GISTs requires accurate diagnosis of this neoplasia vs other soft tissue tumors. 4 Most GISTs occur in the stomach and small intestine, but rarely they also present in the esophagus and large intestine. 5 Differential diagnosis is important since GISTs even with low mitotic rate have a higher risk of malignant behavior and therefore require more aggressive surgery in contrast to, for example, leiomyomas that need to be enucleated only. 6, 7 Several classifications of GISTs exist, one of them is the 'consensus approach of 2002' that considers primary tumor size and mitotic rate. 1 The outcome clearly depends on these two parameters. 8 Tyrosine kinase c-kit (CD117) and PDGFR play important roles for diagnosis and therapy of GISTs. [1] [2] [3] [4] Another immunopathological marker is CD34 that is expressed in 60-70% of cases. [1] [2] [3] [4] [5] [6] [7] [8] [9] A definitive discrimination between benign and malignant GISTs, however, has not been achieved.
Cell adhesion molecule L1 (CD171), a 200-220 kDa type I glycoprotein of the immunoglobulin superfamily, plays a role in development of the nervous system by regulating cell interactions, including neuronal migration. 10, 11 It also mediates neuron-neuron adhesion and neurite outgrowth on Schwann cells. [11] [12] [13] L1 undergoes homophilic binding, but also heterophilic interactions, for example with integrins, have been described. 14,15 L1 was detected on a variety of tumor cells of neuronal, mesothelial and epithelial origin, such as of neuroblastomas, melanomas, lymphomas, small cell lung, colon and breast carcinomas. [16] [17] [18] [19] [20] [21] [22] After cleavage by a metalloproteinase (ADAM10) from the tumor cell surface L1 can be detected in serum of cancer patients. 10, [23] [24] [25] [26] Its presence in tumor and serum has a prognostic significance in ovarian, uterine and renal cell carcinomas and is associated with metastasis of melanomas. 22, 27, 28 The aim of our study was to evaluate whether L1 could serve as a potential diagnostical marker and prognostic factor of GISTs compared to smooth muscle tumors, desmoid-type fibromatosis and PNSTs.
Materials and methods

Patients and Samples
This study was approved by the Ethics Committee of the Chamber of Physicians in Hamburg, Germany. Written informed consent was obtained from all patients for use of the resected samples. For this study, 72 patients with GIST, 29 with smooth muscle tumors, seven with PNSTs and 21 with desmoidtype fibromatosis that were surgically treated between 1985 and 2004 were chosen retrospectively. In 65 patients primary GISTs were examined, among these, additional four liver and two lymph node metastases occurred. In seven patients only liver metastases were available. 18 leiomyomas and 11 leiomyosarcoma (three primary tumors, five liver and two peritoneal metastases), seven PNSTs (five malignant (two primary tumors and three metastases from lung, liver and pancreas) and two benign) and 21 desmoid-type fibromatosis (seven abdominal and 14 extraabdominal) were also analyzed. Tumor samples from patients with mesenchymal tumors from the gastrointestinal tract that were possibly misdiagnosed at times when diagnostic criterias for GIST were not established, were recently reevaluated and re-classified retrospectively. Besides, histological criterias, the following antibodies were used for immunohistological (re-) classification of all tumors: CD117 (c-kit; rabbit polyclonal) (Dako, Glostrup, Denmark), CD34 (mouse IgG1) (Novocastra Laboratories Ltd, Newcastle, United Kingdom), desmin (clone DE-R-11) (Dako), muscle actin (mouse IgG1; clone HHF35) (Enzo Diagnostics Inc., NY, USA), and S-100 protein (polyclonal) (Dako). The proliferative index was determined with Ki-67 (MIB1; IgG1) (Dako) and was categorized as mitotic count of o5/50 high-power fields (HPF), 5-10/50 HPF and 410/50 HPF. All data including sex, histopathological data including tumor size, lymph node metastasis, tumor type and disease stage were obtained from the clinical and pathological records.
Immunohistochemical Staining of L1 and Evaluation of Expression
Immunohistochemical staining for L1 was performed on 5 mm thick sections placed on precoated slides with 3-triethoxysilylpropylamin (Merck, Darmstadt, Germany) of formalin-fixed tissues. After deparaffinization with Rotihistole (Merck) and rehydration in ethanol and TBS (0.05 M; pH 7.6) containing 0.1% Tween 20 (Sigma, Deisenhofen, Germany), tissue sections were pretreated for 30 min in 1% ammonium chloride (NH 4 Cl) in TBS, for 15 min in 0.05 M glycine/TBS and afterwards boiled with ChemMate s Target Retrieval Solution (Dako) in a microwave oven according to the manufacturer's instructions. Staining was performed with the avidin-biotin-peroxidase method (HRP-AEC System, Cell and Tissue Staining Kit; R&D Systems, Minneapolis, MN, USA). The primary antibody, a murine anti-human L1 monoclonal antibody (IgG 1 ; Clone UJ127) (NeoMarkers, Fremont, CA, USA) binding to the extracellular domain of this molecule, was diluted at 1:50 in Antibody Diluent (Dako) and slides were incubated overnight in a humidified chamber at 41C. For each sample one slide, a control section, was incubated with irrelevant murine monoclonal IgG 1 (MOPC21; Sigma) as a negative control to determine unspecific binding. All washing steps were done with TBS containing 0.1% Tween 20. Counterstaining was performed with Mayer's Haematoxylin solution (Merck) for 7 min. Finally, slides were cover-slipped with aqueous mounting medium (Aquatex s ; Merck). Peripheral nerves being present in nearly all sections served as internal positive controls. Additionally, peripheral nerve sections were stained separately. Immunohistochemical analysis and scoring was performed by three independent investigators (JTK, AS and UR).
Survival Data
Clinical follow-up data were obtained by reviewing the hospital records, direct communication with the attending physicians and from the Cancer Registry of Hamburg. Tumor-specific survival was calculated from the date of surgical excision of the primary tumor to the date of death or last follow-up. Patients who died from causes other than GIST were censored at the time of death. Patients whose death was clearly documented as attributable to GIST considered to have died of that disease; other deaths were not considered to have been caused by GIST. Recurrence-free survival was calculated from the date of surgical excision to the date of recurrence. Peritoneal carcinosis was found in two cases and distant metastasis that was exclusively liver metastasis in 10 patients (no other recurrence, for instance lung metastasis or local relapse, was observed in any patient). Only patients with complete follow-up, whose primary tumors had tumor-free resection margins (R0) after surgical removal and no metastasis (M0) at time of surgery were included for survival analysis. Patients that died within 3 months after surgery were excluded. Data with these criterias were available in 55 GIST patients. Two patients died within 3 months after surgery (pulmonary embolism and hemorrhagic shock due to bleeding out of a gastric GIST) and of one patient no follow-up data could be generated. A total of 14 patients were excluded from survival analysis because they either presented with metastatic disease (M1) at initial diagnosis or were not completely resectable (R1 or R2) at primary surgery.
Statistical Analysis
SPSS for Windows (Version 11.5.1) (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Survival curves were plotted using the KaplanMeier method and analyzed using the log-rank test. Cross table statistics were performed with Fisher's test. Association of L1 expression and tumor size were statistically analyzed by unpaired t-test and mitotic count by w 2 test. Significance statements refer to P-values of two-tailed tests that were o0.05.
Results
Characteristics of the Patients
A total of 129 patients were included in our study. Out of these, 72 patients were suffering from GISTs, 29 from smooth muscle tumors (18 from leiomyomas and 11 from leiomyosarcoma), 21 from desmoidtype fibromatosis (seven abdominal and 14 extraabdominal) and seven from PNSTs (five malignant and two benign schwannomas). Patients' characteristics are listed in Table 1 . Briefly, the median age of GIST patients was 61 years, of smooth muscle tumor patients 59 years, of desmoid-type fibromatosis patients 42 years and of PNST patients 43 years. All 72 GISTs were c-kit-positive (100%), 64 (88.9%) were CD34-positive, four (5.6%) positive for S-100 protein, 22 (30.6%) for smooth muscle actin and three (4.2%) for desmin. Concerning 29 smooth muscle tumors, none expressed c-kit, CD34 or S-100, 27 (93.1%) were positive for smooth muscle actin, and 24 (82.8%) for desmin. The seven schwannomas examined were S-100-positive exclusively. All desmoid-type fibromatosis tumors expressed vimentin. Patients' characteristics including location of primary tumors are listed in Table 1 .
L1 Expression in GISTs, Smooth Muscle Tumors, Desmoid-Type Fibromatosis and PNSTs
Of all 72 GIST samples included in this study, 53 (74%) were L1-positive (Table 1) . In contrast, none of 29 immunostained smooth muscle tumor and 21 desmoid-type fibromatosis samples expressed L1. In all, four (57%) of seven immunostained PNSTs were L1-positive. Figure 1 shows representative staining patterns for L1 of a primary GIST and a liver metastasis and coexpression of L1, c-kit and CD34 in a gastric GIST. No differences in terms of positivity or negativity of L1 expression were detected between primary tumors and metastases in any case. For statistical analysis of a correlation between L1 expression in GISTs, smooth muscle tumors, desmoid-type fibromatosis or PNSTs a cross table was used and Fisher's test was applied showing a significant correlation between L1 expression and GISTs in comparison to L1 expression in smooth muscle tumors (Po0.01) and desmoidtype fibromatosis tumors (Po0.01), but not to PNSTs (P ¼ 0.39) ( Table 2) . No correlation was determined between L1 expression and tumor size (P ¼ 0.24 by t-test) or proliferative index (mitotic counts per HPF) of GIST (P ¼ 0.12 by w 2 test). L1 was also expressed on normal interstitial cells of Cajal but not on the smooth muscular cells of the gastrointestinal tract. Interestingly, L1 was expressed in vascular endothelial cells of tumor vessels in smooth muscle tumors, but only in small and not in large vessels of PNSTs and in none of the GISTs examined ( Figure 2 ).
L1 Expression in GISTs and Survival
Follow-up data of patients whose primary GIST was surgically completely resected (R0) and that did not present with distant metastasis (M0) at surgery were generated. Median follow-up time of all patients included for survival analysis (n ¼ 55) was 41 months. The median follow-up time of survivors (n ¼ 43) was 43 months, of L1-negative patients (n ¼ 13) 43 months and of L1-positive patients (n ¼ 42) 41 months. No tumor-specific death was observed in L1-negative patients (n ¼ 13) in contrast to five death events among L1-positive patients (n ¼ 42) (Figure 3) . However, statistical analysis of the results with the log-rank test revealed that this difference did not reach the level of significance (P ¼ 0.13). Analysis of recurrence-free survival revealed that one L1-negative patient developed recurrence in the form of liver metastasis 84 months after surgery (Figure 3 ). Among L1-positive patients, 11 events of recurrence where noted, nine developed liver metastasis and two peritoneal carcinosis. However, this difference was not significant (P ¼ 0.12 by log-rank test). The patient with recurrence in the L1-negative arm is receiving Imatinib since 2002 and is still alive. In the L1-positive arm four patients are on medication with Imatinib since 2001 or 2002 and all are still living. Imatinib is applied to all patients on a daily basis at a dosage of 400 mg orally.
Discussion
In an attempt to identify new markers for the differential diagnosis of GISTs from other soft tissue malignancies, we determined L1 expression in 74% of GISTs but in no smooth muscle tumor or desmoidtype fibromatosis by immunohistochemical analysis. L1 expression was also detected on interstial cells of Cajal believed to be the progenitor cells of GISTs. A trend towards worse outcome of L1-positive patients with no L1-negative patient dying due to GIST was determined, which might turn out to be significant with larger patient numbers and longer follow-up time. Furthermore, four of 11 patients with tumor recurrence within the L1-positive arm with worse survival receive Imatinib and all are still alive, and since this therapy is known to improve outcome Imatinib might rather hide a stronger prognostic impact of L1 expression on survival of GIST patients in the present study. 4 Although c-kit expression is the established standard in the identification of GISTs, additional prognostic markers are required. Cell adhesion molecules have an essential function in tumor progression, and the cell adhesion molecule L1 (CD171) has been paradigmatic. 19 Studies using DNA microarray technique have revealed a distinct gene expression profile in GISTs allowing distinguishing these tumors from mesenchymal malignancies. [29] [30] [31] While high-quality antibodies are often lacking for the genes identified in these studies, L1 can easily be analyzed by immunohistochemistry on formalin-fixed tissues. Expression of malignancy-associated markers, like for instance HIF-1a, STAT3 or VEGF, has been shown in GISTs. [32] [33] [34] The observations of this study are in agreement with previous studies showing expression of L1 in different tumors of neuroectodermal origin, such as melanomas, neuroendocrine tumors of the pancreas and skin. 22, 35, 36 In accordance with our finding, expression of L1 in PNSTs by microarray expression profiling was reported recently. 37 L1 was also described in non-neuroectodermal tumors like uterine, ovarian or colon carcinomas. 28, 38 In some of these studies a correlation with tumor-specific survival was found and the survival data of the present study might be a hint towards a similar finding in GISTs. GISTs have also been shown to express other proteins of the nervous system, such as glial fibrillary acidic protein (GFAP) and neurofilament. 39 The present study shows that a neuronal adhesion molecule like L1 can also be highly expressed in GISTs. A metalloproteinase (ADAM10) cleaves L1 from the tumor cell surface and soluble L1 was detected in serum of tumor patients proposing an additional diagnostic tool in GIST patients. 28 A differential expression pattern on tumor vessels was found as a bystander result in this study. L1 was not detected in vascular endothelial cells in tumor vessels of GISTs, but on small vessels of PNSTs and small and large vessels of L1-negative leiomyomas and leiomyosarcoma. Given that tumor cells expressing L1 can interact with multiple vascular or platelet integrins, L1 up-regulation could play an important role in extravasation of tumor cells during metastatic spread. 25 Expression of L1 was also described in tumor vessels in renal cell carcinomas. 27 The present study represents a similar finding, however, the reason for the vascular L1 expression in smooth muscle tumors and PNSTs but not in GISTs remains unclear. Further examinations have to elucidate a possible role of L1 in tumor angiogenesis in different tumor entities.
In summary, our results indicate that L1 is highly expressed in GISTs and at least hint towards a negative impact on survival and recurrence. L1 could serve as a tumor marker in differential diagnosis with regard to other soft tissue tumors in general, but particularly pertinent to smooth muscle tumors and desmoid-type fibromatosis of the gastrointestinal tract. Future studies might focus on detection of L1 in the serum of GIST patients and further examine the impact of L1 expression on survival.
